Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

Abstract

The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an increase in the reported incidence, severity of cases, and rate of mortality and relapses. These increases have primarily affected some special populations including the elderly, patients requiring concomitant antibiotic therapy, patients with renal failure, and patients with cancer. Until recently, the treatment of CDI was limited to either metronidazole or vancomycin. New therapeutic options have emerged to address the shortcomings of current antibiotic therapy. Fidaxomicin stands out as the first-in-class oral macrocyclic antibiotic with targeted activity against C. difficile and minimal collateral damage on the normal colonic flora. Fidaxomicin has demonstrated performance not inferior to what is considered the “gold standard” available therapy for CDI, vancomycin, in two separate Phase III clinical trials, but with significant advantages, including fewer recurrences and higher rates of sustained clinical cures. Fidaxomicin constitutes an important development in targeted antibiotic therapy for CDI and must be considered as a first-line agent for patients with risk factors known to portend relapse and severe infection.

Keywords:

• fidaxomicin
• Clostridium difficile-associated diarrhea
• CDAD
• Clostridium difficile infection (CDI)
• vancomycin
• metronidazole

Disclosure

Fredy Chaparro-Rojas has no conflicts of interest to report. Kathleen M Mullane is on advisory boards for Optimer Pharmaceuticals and Merck and is involved in clinical trials for Actelion Pharmaceuticals, Astellas Pharma, Chimerix, Merck, Optimer Pharmaceuticals, and ViroPharma. The authors report no other conflicts of interest in this work.